Figure 5.

Tumor treatment by LFnCdtB in a mouse model. 10–13 C57BL/6 mice per group were injected subcutaneously with LL3 mouse melanoma tumors on day 0. Injection of PA+LFnCdtB or tumor-specific PA-L1+LFnCdtB fusion into the mouse peritoneum was performed on days 5, 7, 9, 12, 14, and 16 (arrows) using either PBS (black line), 100 μg wild-type PA+100 μg LFnCdtB (blue line) or 100 μg PA-L1+100 μg LFnCdtB (red line). (a) Relative mean mouse body weight until day 19. Error bars indicate the S.D. (b) Mean tumor masses until day 19. Tumor mass was calculated from measurements of the tumor width, depth, and height